Google Custom Search
Podcast Advocacy 2014 HBV Meeting navigation menu

Home

PA Biotech
Visit our Baruch Blumberg Institute of Living Science
World Hepatitis Alliance Member
HepB United
Prevention and Vaccination
 

HBF Drug Watch

Compounds in Development for Chronic Hepatitis B

Updated April 27, 2015

FAMILY/DRUG NAME MECHANISM COMPANY STATUS
Interferons - Mimic naturally-occurring, infection-fighting immune substances produced in the body
Intron A
(Interferon
alfa-2b)
Immunomodulator Merck,
Whitehouse Station, NJ
FDA Approved
1991
Pegasys
(Peginterferon alfa-2a)
Immunomodulator Genentech,
South San Francisco, CA
FDA Approved 2005
There are other brands of interferon approved for HCV treatment, but they have not been FDA-approved for HBV: Wellferon (Glaxo), Roferon(Hoffman-La Roche), and Infergen (Amgen)
Nucleoside Analogues -  Interfere with the viral DNA polymerase enzyme used for hepatitis B virus reproduction
Epivir-HBV
(Lamivudine)
Inhibits viral DNA polymerase GlaxoSmithKline, Philadelphia, PA FDA Approved
1998
Hepsera
(Adefovir Dipivoxil)
Inhibits viral DNA polymerase Gilead Sciences,
Foster City, CA
FDA Approved
2002
Baraclude
(Entecavir)
Inhibits viral DNA polymerase Bristol-Myers Squibb,
Princeton, NJ
FDA Approved
2005
Tyzeka
(Telbivudine)
Inhibits viral DNA polymerase Novartis,
Switzerland
FDA Approved
2006
Viread
(Tenofovir)
Inhibits viral DNA polymerase Gilead Sciences,
Foster City, CA
FDA Approved 2008
Clevudine
(L-FMAU)
Inhibits viral DNA polymerase Bukwang,
South Korea
Eisai, Japan
Approved S. Korea
2006 (Levovir)
Tenofovir alafenamide (TAF)
Prodrug of Tenofovir Gilead Sciences,
Foster City, CA
Phase III
CMX157 Prodrug of Tenofovir ContraVir Pharmaceuticals,
Edison, NJ
Phase II
AGX-1009 Prodrug of Tenofovir Agenix, Australia Phase I, China
Non-Nucleoside Antivirals -  Interfere with proteins involved in viral reproduction
Myrcludex B Entry Inhibition Hepatera, Russia with Myr-GmbH, Germany Phase II for HBV and HDV
ARC-520 RNAi gene silencer Arrowhead Research, Pasadena, CA Phase II/III
NVR-1221
(NVR 3-778) 
Capsid inhibitor Novira Therapeutics, Doylestown, PA Phase IIa
SB 9200 Small molecule nucleic acid hybrids or “SMNH” Spring Bank Pharma,
Milford, MA
Phase II
Rep 2139 (REP 9AC) HBsAg Release Inhibitor REPLICor Inc.,
Canada
Phase II
Birinapant
(TL32711)
SMAC inhibitor

TetraLogic,
Malvern, PA

Phase I/IIa
Bay 41-4109 Inhibits viral nucleocapsid AiCuris, Germany Phase I
TKM-HBV HBsAg inhibitor Tekmira,
Canada
Phase I
SB 9200 Small molecule nucleic acid hybrids or “SMNH” Spring Bank Pharma,
Milford, MA
Phase II
Alinia (Nitazoxanide) Small Molecule Romark Labs,
Tampa, FL
Preclinical
dd-RNAi compound Gene silencing Benitec, Australia
and Biomics, China
Preclinical
BSBI-25 cccDNA inhibitor Baruch S. Blumberg Institute,
Doylestown, PA
Preclinical
CpAMS HBV Core Protein Assembly Biosciences, NY, NY Preclinical
NVPO18 Cyclophilin inhibitor Neurovive, Sweden Preclinical
ALN-HBV RNAi gene silencer

Alnylam,
Cambridge, MA

Preclinical
CPI-431-32 Cyclophilin inhibitor

Ciclofilin Pharma,
San Diego, CA

Preclinical
Non-Interferon Immune Enhancers -  Boost T-cell infection-fighting immune cells and natural interferon production
ABX 203 Therapeutic vaccine ABIVAX,
Paris, France
Phase IIb/III
GS-4774 Therapeutic vaccine Gilead Sciences with Globe Immune,
Louisville, CO
Phase II
GS-9620 TLR7 agonist Gilead Sciences,
Foster City, CA
Phase II
CYT107
(Interleukin-7)
Immunemodulator Cytheris,
France
Phase I/IIa
TG 1050 Immunotherapeutic Transgene,
Shanghai
Phase I
INO-1800 Therapeutic vaccine Inovio,
Blue Bell, PA
Phase I
Hepatitis Delta Virus (HDV) Drug Watch
Mycludex B Prenylation Inhibitor Hepatera, Russia with Myr-GmbH, Germany Phase II for HBV and HDV
Lonafarnib Prenylation Inhibitor Eiger BioPharmaceuticals, Palo Alto, CA Phase II for HDV
Rep 2139 HBsAg Release Inhibitor  REPLICor, Canada Phase II for HDV

 

Page last modified April 27, 2015


donate
amazon smile

Connect with Us

facebook twitter youtube linkedin
Hep B Blog
Bookmark and Share
Site design by Ferguson Lynch  FL logo